Extracellular ATP, hemopexin and vascular alterations in Preeclampsia*

Completed

Conditions: preeclampsia
10026908
10057166

Registration Number: NL-OMON37052

Lead Sponsor: niversitair Medisch Centrum Groningen

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 295

Inclusion Criteria

Experiment 1: Pregnant women who have been diagnosed to be at increased risk for developing preeclampsia, i.e. women who have been diagnosed with pre-existent hypertension, diabetes mellitus, vasculitis, renal disease, autoimmune disease, malignancy, or women with preeclampsia in their previous pregnancy, women carrying twins. ;Experiment 2:
Preeclamptic patients:
* Preeclampsia defined by the ISSHP criteria (see onderzoeksprotocol)
* Primigravid
* Age: >/<= 18 years and <40 years;Pregnant women who deliver preterm
* preterm delivery, i.e. before 36 weeks
* Age: >/<=18 years and <40 years;Pregnant women who deliver a growth restricted baby
* IUGR * Age: >/<=18 years and <40 years;Normal pregnant women:
* Primigravid
* Age: >/<= 18 years and <40 years;Control non-pregnant women :
* Healthy nulligravid women
* Age: >/<= 18 years and <40 years

Exclusion Criteria

Experiment 1: pregnant women without an increased risk of developing preeclampsia;Experiment 2:
Preeclamptic women:
Diagnosis of pre-existent hypertension,
diabetes mellitus,
vasculitis,
renal disease,
autoimmune disease,
malignancy, ;Healthy pregnant women:
* Multiparity
* Multiple pregnancy
* Fetal growth retardation
* Other pregnancy complications
* Hypertension
* Any known chronical illnesses
* Age: <18 years and >40 years
* smoking;Control non-pregnant women:
* Multiparity
* Age: <18 years and >40 years
* Existence of any known diseases
* smoking;pregnant women with preterm delivery
Diagnosis of
Treated pre-existent hypertension,
diabetes mellitus,
vasculitis,
renal disease,
autoimmune disease,
malignancy,
signs of infection

Study & Design

Study Type: Observational invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Experiment 1: Blood samples (10 ml heparinised and 10 ml EDTA) of 135 pregnant<br /><br>women at high risk for developing preeclampsia will be taken at weeks 10, 14,<br /><br>18, 20 and 25, 30, 35 and 40 of pregnancy. We will measure plasma hemopexin<br /><br>activity and plasma ATP levels as well as various inflammatory parameters.<br /><br>Experiment 2: Blood samples (10 ml EDTA, 10 ml heparinised blood) will be taken<br /><br>from women diagnosed with preeclampsia (ISSHP criteria). We will measure<br /><br>activation of inflammatory cells and plasma concentrations of hemopexin, ATP,<br /><br>inflammatory parameters and other factors suggested to be involved in the<br /><br>pathogenesis of preeclampsia. In tissue biopsies we will measure endothelial<br /><br>cell activation and dysfunction. </p><br>

Secondary Outcome Measures